News / Taiwan / economic_daily
US Import Tariffs on Generic Drugs Create Opportunities for Taiwanese Pharma Firms
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-08-23
1795, 4105, 6446, 6472
The US will impose steep tariffs on imported generic drugs by 2028, forcing global manufacturers to localize production and benefiting Taiwanese firms like Bora and PharmaEssentia.
What Happened
Tariff Policy Shift: The US government has introduced a two-year grace period for imported generic drugs before implementing punitive tariffs of 100% to 200% starting in 2028. This policy is designed to compel global pharmaceutical companies to establish manufacturing facilities within the United States to ensure supply chain resilience.
Global Supply Chain Impact: Major generic drug exporters, particularly India and China, face significant headwinds as their reliance on US exports becomes a liability under the new regime. This structural change aims to force manufacturers to localize production or risk losing access to the lucrative American market.
Taiwanese Strategic Advantage: Taiwanese pharmaceutical companies are well-positioned to benefit from this shift due to their relatively small existing export footprint and strategic investments. Firms like Bora Pharmaceuticals have already secured US-based production sites through acquisitions, allowing them to bypass tariffs and capture redirected orders.
Regulatory Moats: Companies like PharmaEssentia remain insulated from these trade barriers, as their rare disease drug Besremi has secured orphan drug tax exemptions. Similarly, TTY Biopharm’s specialized products continue to benefit from high regulatory standards, ensuring stable growth despite the broader geopolitical shifts in the pharmaceutical industry.